Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 29, 2012New England Journal of MedicineOpen Access

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

CHClaire HarrisonNational Health ServiceJKJean‐Jacques KiladjianDélégation Paris 5HAHaifa Kathrin Al‐AliNovartis (Switzerland)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Harrison et al. (2012) studied this question.

synapsesocial.com/papers/69d6c1aefca0359822aa8467https://doi.org/10.1056/nejmoa1110556
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.2003 · 1,529 citations
  2. 2Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT2008 · 7 citations
  3. 3Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.2009 · 18 citations
  4. 4Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms2010 · 330 citations
  5. 5Validation of the Functional Assessment of Cancer Therapy–Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma2008 · 41 citations